- Home
- GMAB vs BG Comparison
GMAB vs BG Comparison
Compare GMAB & BG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- BG
- Stock Information
- Founded
- GMAB 1999
- BG 1818
- Country
- GMAB Denmark
- BG United States
- Employees
- GMAB N/A
- BG N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- BG Packaged Foods
- Sector
- GMAB Health Care
- BG Consumer Staples
- Exchange
- GMAB Nasdaq
- BG Nasdaq
- Market Cap
- GMAB 12.8B
- BG 10.8B
- IPO Year
- GMAB N/A
- BG N/A
- Fundamental
- Price
- GMAB $19.88
- BG $81.54
- Analyst Decision
- GMAB Buy
- BG Buy
- Analyst Count
- GMAB 9
- BG 5
- Target Price
- GMAB $39.17
- BG $81.60
- AVG Volume (30 Days)
- GMAB 1.5M
- BG 1.7M
- Earning Date
- GMAB 05-08-2025
- BG 05-07-2025
- Dividend Yield
- GMAB N/A
- BG 3.44%
- EPS Growth
- GMAB 85.27
- BG N/A
- EPS
- GMAB 17.68
- BG 7.82
- Revenue
- GMAB $3,135,137,804.00
- BG $51,334,000,000.00
- Revenue This Year
- GMAB $17.69
- BG $2.71
- Revenue Next Year
- GMAB $14.81
- BG $1.95
- P/E Ratio
- GMAB $1.12
- BG $10.42
- Revenue Growth
- GMAB 51.92
- BG N/A
- 52 Week Low
- GMAB $17.24
- BG $67.40
- 52 Week High
- GMAB $30.41
- BG $114.92
- Technical
- Relative Strength Index (RSI)
- GMAB 48.84
- BG 58.64
- Support Level
- GMAB $18.89
- BG $78.10
- Resistance Level
- GMAB $19.67
- BG $83.88
- Average True Range (ATR)
- GMAB 0.49
- BG 2.41
- MACD
- GMAB -0.12
- BG 0.18
- Stochastic Oscillator
- GMAB 34.61
- BG 73.65
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About BG Bunge Limited
Bunge Global SA formerly Bunge Ltd is an agribusiness and food company with operations along the farm-to-consumer food chain. The company segments include Agribusiness; Refined and Specialty Oils; Milling; Sugar and Bioenergy and Corporate and Other. It generates maximum revenue from the Agribusiness segment. The company is an oilseed processor and producer of vegetable oils and protein meals, based on processing capacity, a grain processor, the seller of packaged plant-based oils, producer and seller of wheat flour, bakery mixes and corn-based products in North and South America.